Jardiance and Steglatro are two medications that belong to the class of drugs known as SGLT2 inhibitors, which are primarily used to manage type 2 diabetes. As the prevalence of diabetes continues to rise globally, the importance of understanding various treatment options becomes increasingly significant. Both Jardiance (empagliflozin) and Steglatro (ertugliflozin) offer unique benefits and potential side effects that can influence a patient’s choice of treatment. The mechanism of action for these medications revolves around helping the kidneys eliminate excess glucose through urine, thus lowering blood sugar levels. Patient experience, efficacy, and safety profiles are key considerations when evaluating these medications. With the growing emphasis on personalized medicine, understanding how…